Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 6/20 | 0.67 |
| ▸ | AR | P10275 | 4/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.67 |
| ▸ | NR3C2 | P08235 | 6/20 | 0.62 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 5/20 | 0.53 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | SHBG | P04278 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amebucort SCHEMBL10408572 | 1.00 | PGR (0.67) | PGRARCHRM1NR3C2NR3C1 | |
| SCHEMBL10408593 | 0.96 | PGR (0.66) | PGRARCHRM1NR3C2NR3C1 | |
| SCHEMBL10408758 | 0.95 | NR3C2 (0.64) | PGRARCHRM1NR3C2NR3C1 | |
| SCHEMBL10408757 | 0.95 | NR3C2 (0.64) | PGRARCHRM1NR3C2NR3C1 | |
| SCHEMBL10408599 | 0.94 | PGR (0.61) | PGRARCHRM1NR3C2NR3C1 | |
| SCHEMBL10408760 | 0.94 | PGR (0.63) | PGRARCHRM1NR3C2NR3C1 | |
| SCHEMBL10408598 | 0.94 | PGR (0.61) | PGRARCHRM1NR3C2NR3C1 | |
| SCHEMBL10408761 | 0.94 | PGR (0.63) | PGRARCHRM1NR3C2NR3C1 | |
| SCHEMBL10409163 | 0.94 | PGR (0.76) | PGRARCHRM1NR3C2NR3C1 | |
| SCHEMBL10409166 | 0.94 | PGR (0.76) | PGRARCHRM1NR3C2NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-4912098-A | Antiinflammatory 6 alpha-methylhydrocortisones | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-03-27 | — | — | US | claimed |
| US-20260124244-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | STELLULAR BIO, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4646217-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | Stellular Bio, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | disclosed |
| WO-2024148315-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | STELLULAR BIO, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| CN-116615210-A | Novel anuclear cells as a source for the treatment of platelet-rich plasma-dependent disorders | 血小板生源说股份有限公司 | 2023-08-18 | — | — | CN | disclosed |
| US-20230174939-A1 | NOVEL ANUCLEATED CELLS AS A SOURCE FOR TREATMENT OF PLATELET RICH PLASMA DEPENDENT DISORDERS | STELLULAR BIO, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| EP-4149497-A1 | NOVEL ANUCLEATED CELLS AS A SOURCE FOR TREATMENT OF PLATELET RICH PLASMA DEPENDENT DISORDERS | Platelet Biogenesis, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| EP-4125947-A1 | NOVEL ANUCLEATED CELLS FOR THE TREATMENT OF DISEASES | Platelet Biogenesis, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
| EP-0098568-B1 | CORTICOIDS-CONTAINING PREPARATION FOR TOPICAL APPLICATION | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-08-28 | — | — | EP | disclosed |
| EP-0098566-B1 | CORTICOIDS-CONTAINING PREPARATION FOR TOPICAL APPLICATION | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-08-21 | — | — | EP | disclosed |
| US-4918065-A | ANTIINFLAMMATORY AGENT | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-04-17 | — | — | US | disclosed |
| US-4912098-A | Antiinflammatory 6 alpha-methylhydrocortisones | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-03-27 | — | — | US | disclosed |
| EP-0098568-A2 | Corticoids-containing preparation for topical application | SCHERING AKTIENGESELLSCHAFT (DE) | 1984-01-18 | — | — | EP | disclosed |
| EP-0098566-A2 | Corticoids-containing preparation for topical application | SCHERING AKTIENGESELLSCHAFT (DE) | 1984-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124244-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | MYH10, PDGFA, MPL | PGR 157/4885AR 4167/4885CHRM1 1821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.